Shattuck Labs is a biotechnology company focused on developing antibodies for inflammatory and immune-mediated diseases. The company's approach centers on targeting the DR3 receptor pathway to modulate immune responses. Its lead product candidate, SL-325, is a DR3 blocking monoclonal antibody currently in development. The company is also advancing SL-425 and multiple preclinical bispecific antibodies that combine DR3 targeting with other clinically validated targets, with initial focus on inflammatory bowel disease applications.
Beyond its DR3-focused pipeline, Shattuck Labs maintains a preclinical oncology program targeting TRIM7 inhibitors for future internal pipeline development. The company does not appear to have approved products generating commercial revenue, operating as a clinical-stage biotech organization.
Based in Austin, Texas, Shattuck Labs operates with a team of 44 full-time employees. The company was incorporated in Delaware in 2016 and is listed on Nasdaq, with a market capitalization of approximately $0.2 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.49 | $-1.49 | +27.3% | |
| 2023 | $-2.05 | $-2.05 | +14.9% | |
| 2022 | $-2.41 | $-2.41 | -125.2% | |
| 2021 | $-1.07 | $-1.07 | — | |
| 2020 | — | — | — |